Chemical formula: C₂₇H₂₉N₅O₆S Molecular mass: 551.614 g/mol PubChem compound: 104865
Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A and B (ETA and ETB) receptors. Bosentan decreases both pulmonary and systemic vascular resistance resulting in increased cardiac output without increasing heart rate.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C02KX01 | Bosentan | C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KX Antihypertensives for pulmonary arterial hypertension |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TRACLEER Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Bosentan is an active ingredient of these brands:
United States (US)Brazil (BR)Canada (CA)France (FR)Germany (DE)Italy (IT)Japan (JP)Mexico (MX)Netherlands (NL)New Zealand (NZ)Tunisia (TN)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
